Qualisure

Qualisure Diagnostics: Building the Infrastructure for Next-Generation Precision Oncology

Qualisure Diagnostics is a Calgary-based precision oncology company redefining how molecular diagnostics are developed, deployed, and scaled. Founded by clinician-scientists and engineers, the company sits at the intersection of cancer biology, artificial intelligence, and health system implementation. Its mission is simple but ambitious: to make advanced diagnostic biomarkers accessible to patients worldwide, regardless of where they are tested.

Data is readily available, but getting clinical insights from the data is challenging. Even today, most clinical decisions still rely on tumour size, histopathology, and a small number of genetic mutations. These features often fail to capture the true biological behaviour of a tumour. As a result, patients with seemingly similar cancers can experience dramatically different outcomes, leading to both overtreatment and undertreatment. In order to more precisely direct treatment choices, it will be imperative to leverage the extensive data available to us, including sequencing data.

At the same time, the infrastructure required to deliver advanced molecular diagnostics remains highly centralized. Tests are typically developed, validated, and run in single reference laboratories, creating bottlenecks in access, limiting global scalability, and increasing costs. This model is particularly challenging for health systems outside major urban centers or in international markets where data sovereignty and local testing requirements are critical.

Qualisure’s solution is Molecular deCodeR™ (MDR), a software platform that allows labs to perform testing locally, while diagnostic developers deploy and manage their algorithms from a central platform. This approach allows diagnostic developers to partner with labs that already have the necessary capabilities, avoiding the cost of building infrastructure and enabling faster market entry.

Thyroid GuidePx® serves as the company’s proof of concept. This transcriptomic test analyzes gene expression patterns in papillary thyroid cancer to predict recurrence risk and inform treatment decisions, including the extent of surgery and use of radioactive iodine. Unlike traditional approaches, it captures the underlying biology of the tumour, demonstrating that molecular insight can meaningfully change clinical management. Importantly, Thyroid GuidePx has been deployed across multiple institutions and geographies, illustrating the feasibility of Qualisure’s decentralized model.

Building on this foundation, Qualisure is now advancing the next phase of its platform: developing algorithms that are independent of laboratory technology and workflow. By standardizing how biological data is interpreted—regardless of how it is generated—the company aims to eliminate a major barrier to global adoption: the need to repeatedly redevelop and revalidate tests across different environments.

The long-term vision is to create a scalable, software-enabled infrastructure for precision oncology—one that allows new diagnostics to be developed rapidly, deployed globally, and integrated seamlessly into clinical care. In doing so, Qualisure is not just developing individual tests; it is building the foundation for a new model of cancer diagnostics—one that is decentralized, data-driven, and centered on the biology of disease.

Qualisure is enabling diagnostic developers to bring advanced diagnostics to patients worldwide through simplified deployment and a secure, scalable platform. To learn more, contact ryan.sayers@qualisuredx.com